NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES FINAL RESULTS OF RIGHTS OFFERING

Rhea-AI Summary

Neuberger High Yield Strategies Fund (NYSE American: NHS) announced final results of its transferable rights offering, which expired April 15, 2026. The final subscription price was $6.50 per share, equal to 92.5% of NAV at the close on the expiration date.

The Offer was over-subscribed and will result in issuance of 10,463,948 shares for gross proceeds of approximately $68.0 million. Subscribed shares are expected to be issued on or about April 21, 2026, with excess payments returned to subscribers. Over-subscription allocations will be made pro-rata to record-date stockholders who submitted requests.

Positive

• Gross proceeds of approximately $68.0 million
• Issuance of 10,463,948 shares to strengthen capital base
• Subscription price set at 92.5% of NAV may attract investor participation

Negative

• Over-subscription led to pro-rata allocation, limiting some investors' full requests
• Issuance of 10.46 million shares may dilute existing shareholders proportionally

News Market Reaction – NHS

-1.76%

-1.76% Session close to close

In the Apr 21 session, NHS declined 1.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement finalizes NHS’s transferable rights offering, confirming a subscription price of $...

Analysis

This announcement finalizes NHS’s transferable rights offering, confirming a subscription price of $6.50, issuance of 10,463,948 shares, and expected gross proceeds of $68.0 million. It follows March’s launch terms and April’s preliminary results, closing a multi-step capital raise. Investors may track how the increased share count interacts with the fund’s existing leverage, distribution level of $0.0905 per share, and ongoing performance versus its benchmark.

Key Figures

Subscription price: $6.50 per share NAV reference: 92.5% of NAV New shares issued: 10,463,948 shares +5 more

8 metrics

Subscription price $6.50 per share Final rights offering subscription price, set at 92.5% of NAV

NAV reference 92.5% of NAV Subscription price set as 92.5% of NAV on April 15, 2026

New shares issued 10,463,948 shares Common stock to be issued through the over-subscribed rights offering

Gross proceeds $68.0 million Expected gross proceeds from the completed rights offering

Expiration time 5:00 PM Eastern Rights offering expiration time on April 15, 2026

Expiration date April 15, 2026 Rights offering expiration date

Share issuance date April 21, 2026 Expected date subscribed shares are issued

Information agent phone (800) 290-6428 Contact for investor inquiries regarding the rights offering

Previous Offering Reports

2 past events · Latest: Apr 16 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Offering prelim results	Negative	+0.1%	Preliminary rights offering results with discounted pricing and oversubscription details.
Mar 12	Rights offering launch	Negative	-3.7%	Announcement of transferable rights offering and discounted subscription terms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-related headlines have produced mixed reactions: one negative move aligned with dilution concerns and one small positive move diverging from that pattern.

Recent Company History

Over recent months NHS has focused on funding and income stability. A February 27 N-CSR highlighted a 9.03% NAV total return and leverage usage, while recurring monthly distributions of $0.0905 per share were maintained. In March, the fund launched a transferable rights offering, followed by preliminary results on April 16. Today’s final results confirm the same pricing and size, closing the capital-raise sequence signaled in prior offering updates.

Key Terms

transferable rights offering, net asset value, over-subscription privilege, prospectus

4 terms

transferable rights offering financial

"announced today the final results of its transferable rights offering (the "Offer")"

A transferable rights offering is a company raising money by giving existing shareholders tradable tokens called “rights” that let them buy new shares at a set price. Think of it like a coupon that shareholders can either use to buy discounted stock, sell to someone else, or let expire; it matters to investors because exercising preserves ownership percentage while selling can provide cash, and the overall offering can dilute share value for those who do nothing.

net asset value financial

"was $6.50, which was equal to 92.5% of the Fund's net asset value per share"

Net asset value is the total value of an investment fund's assets minus any liabilities, divided by the number of shares or units outstanding. It represents the per-share worth of the fund, similar to how the value of a house is determined by its total worth after debts are subtracted. Investors use it to gauge the true value of their holdings and to compare different investment options.

View in glossary

over-subscription privilege financial

"shares issued as part of the over-subscription privilege of the Offer will be allocated"

An over-subscription privilege is a feature of a share offering that lets existing investors request more shares than their initial entitlement, with any extra allocation given only if other investors do not take their full allotment. It matters because it gives shareholders a chance to increase their stake and avoid losing ownership percentage, much like ordering extra slices at a party in case others pass—however, receiving the extras is not guaranteed.

prospectus regulatory

"This document is not an offering, which can only be made by a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 20, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced today the final results of its transferable rights offering (the "Offer"), which expired at 5:00 P.M. Eastern Time on April 15, 2026 (the "Expiration Date").

The final subscription price per share of common stock of the Fund ("Common Stock") was $6.50, which was equal to 92.5% of the Fund's net asset value per share of Common Stock at the close of trading on the NYSE American on the Expiration Date.

The Offer, which was over-subscribed, will result in the issuance of 10,463,948 shares of Common Stock. The gross proceeds of the Offer are expected to be approximately $68.0 million. The shares of Common Stock subscribed for are expected to be issued on or about April 21, 2026. The Fund will return to subscribing investors the full amount of any excess payments.

The Offer was over-subscribed, and the over-subscription requests exceeded the over-subscription shares available. Accordingly, the shares issued as part of the over-subscription privilege of the Offer will be allocated pro-rata among record date stockholders who submitted over-subscription requests based on the number of rights originally issued to them by the Fund.

This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund's investment objective, risks, charges and expenses carefully before investing. Copies of the Fund's prospectus supplement and accompanying prospectus and other documents the Fund has filed with the Securities and Exchange Commission may be obtained by visiting the EDGAR database on the SEC's website at www.sec.gov.

Inquiries regarding the Offer should be directed to the Fund's Information Agent, EQ Fund Solutions, LLC, at (800) 290-6428.

About Neuberger High Yield Strategies Fund Inc. The Fund's investment objective is to seek high total return (income plus capital appreciation). Under normal market conditions, the Fund invests at least 80% of its total assets in high yield debt (below investment grade) securities of U.S. and foreign issuers. The Fund may invest up to 20% of its total assets in other securities and financial instruments, and up to 15% of its total assets in collateralized loan obligations.

About Neuberger

Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger's investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again in 2025, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards. Data as of March 31, 2026.

Contact:
Neuberger Berman Investment Advisers LLC
Investor Information
(877) 461-1899

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuberger-high-yield-strategies-fund-announces-final-results-of-rights-offering-302747821.html

SOURCE Neuberger Berman

FAQ

How many shares did NHS issue in the April 2026 rights offering?

NHS issued 10,463,948 shares as a result of the rights offering. According to the company, those shares were the total to be issued following an over-subscribed offering that closed April 15, 2026.

What were the proceeds and subscription price for NHS rights offering?

The offering raised about $68.0 million at a subscription price of $6.50 per share. According to the company, $6.50 equaled 92.5% of the Fund's NAV at the close on the expiration date.

When will NHS issue the shares from the rights offering (NHS)?

Subscribed shares are expected to be issued on or about April 21, 2026. According to the company, excess payments will be returned to subscribing investors at that time.

How were over-subscription requests allocated in the NHS offering?

Over-subscription shares were allocated pro-rata among record-date stockholders who submitted requests. According to the company, allocations were based on the number of rights originally issued to each record-date stockholder.

Will investors receive refunds for excess payments in the NHS offering?

Yes; the Fund will return the full amount of any excess payments to subscribing investors. According to the company, excess payments will be returned when subscribed shares are issued.

Where can investors find the NHS prospectus and offering documents?

Investors can obtain the prospectus supplement, accompanying prospectus, and SEC filings via the EDGAR database. According to the company, documents are available on the SEC website at www.sec.gov.